DFTX: financial statements from SEC — TradeAlmanac

DFTX

Definium Therapeutics, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Research and development	41m	31m	30m	23m	17m	15m
Selling, general and administrative	18m	15m	11m	9m	8m	10m
Operating expenses	59m	46m	41m	32m	25m	24m
Operating income	−59m	−46m	−41m	−32m	−25m	−24m
Interest expense	1m	1m	2m	602,000	727,000	466,000
Net income	−77m	−67m	−43m	−23m	−14m	−6m
Earnings per share	−0.71	−0.78	−0.50	−0.27	−0.18	−0.08
Earnings per share, diluted	−0.71	−0.78	−0.50	−0.35	−0.27	−0.26
Weighted average shares	109m	86m	85m	85m	78m	72m
Weighted average shares, diluted	109m	86m	85m	87m	80m	75m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	263m	258m	20m	33m	83m	274m	295m	243m
Short-term investments	111m	154m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−43m	−29m
Investing cash flow	42m	−162m
Financing cash flow	5m	1m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)